Day One Biopharmaceuticals, Inc.
NASDAQ: DAWN0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- NASDAQ Global Select
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Jeremy Bender
- Employees
- 181
- Headquarters
- Brisbane, United States
- IPO year
- 2021
- Market cap
- $2.2B
- Website
- https://dayonebio.com
Loading DAWN…
Loading profile data…Frequently asked questions about DAWN
What does Day One Biopharmaceuticals, Inc. (DAWN) do?
Operating as a clinical-stage biopharmaceutical entity, Day One Biopharmaceuticals, Inc. is dedicated to discovering and commercializing precise therapeutic options for individuals battling genetically defined cancers. A key asset is DAY101, an orally administered, brain-permeable type II pan-rapidly accelerated fibrosarcoma kinase inhibitor, cu...
Where does DAWN trade?
Day One Biopharmaceuticals, Inc. (DAWN) trades on the NASDAQ Global Select.
What sector is DAWN in?
Day One Biopharmaceuticals, Inc. (DAWN) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Day One Biopharmaceuticals, Inc.?
Jeremy Bender is the chief executive officer of Day One Biopharmaceuticals, Inc. (DAWN).
Where is Day One Biopharmaceuticals, Inc. headquartered?
Day One Biopharmaceuticals, Inc. is headquartered in United States.
Does DAWN pay a dividend?
Day One Biopharmaceuticals, Inc. (DAWN) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did DAWN go public?
Day One Biopharmaceuticals, Inc. (DAWN) completed its initial public offering in 2021.